Laurus Labs (LAURUSLABS.NS) Osake Kurssi
Laurus Labs Kurssi
Liikevaihto on kasvanut 18,9 % vuodessa viimeisten 13 vuoden aikana 68,13 Mrd. INR:een. Osakekohtainen tulos on kasvanut 19,4 % vuodessa viimeisten 13 vuoden aikana. Laurus Labsn nettomarginaali on nyt 13,0 %, laskenut 16,8 %:sta muutama vuosi sitten. Laurus Labsn osinkotuotto on tällä hetkellä noin 0,08 %. Jakosuhde on noin 21 % tuloksesta. Osinko on kasvanut 20,4 % vuodessa viimeisten 9 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 1 060,80 INR, eli ali nykyhintaa 47,2 %. 20 analyytikosta 5 suosittaa ostoa — kokonaiskonsensus on Myy.
Laurus Labs osakekurssi
Laurus Labs liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Laurus Labs -osakkeesta
Laurus Labs Ltd is primarily present in various countries and regions across the globe. The company has established a significant presence in India, where its headquarters are located. In addition, Laurus Labs Ltd has a strong presence in the United States, Europe, and other key markets. With its comprehensive global reach, the company is able to cater to a diverse customer base and leverage its international operations for growth and market expansion.
The business model of Laurus Labs Ltd is centered around the development, manufacturing, and marketing of generic active pharmaceutical ingredients (APIs) and formulations. Laurus Labs specializes in offering cost-effective and high-quality healthcare solutions, serving both domestic and international markets. The company operates across various segments such as APIs, generic formulations, synthesis and nutraceuticals. Laurus Labs focuses on innovation, research and development, and maintaining strong customer relationships to drive growth and expansion in the pharmaceutical industry. With its expertise in the production of APIs and formulations, Laurus Labs aims to provide affordable healthcare solutions, contributing to the betterment of global health.
Laurus Labs Ltd is primarily active in the pharmaceutical industry.
The main competitors of Laurus Labs Ltd in the market include generic pharmaceutical companies such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Cipla Limited, Lupin Limited, and Aurobindo Pharma. These companies also specialize in the production and distribution of generic drugs, actively competing with Laurus Labs in terms of product offerings, pricing, and market share.
Laurus Labs Ltd, founded in 2005, is a leading research-driven pharmaceutical company based in Hyderabad, India. With a focus on developing and manufacturing high-quality generic Active Pharmaceutical Ingredients (APIs) and finished dosage forms, Laurus Labs has emerged as a global leader in the healthcare industry. The company's strong commitment to innovation, quality, and sustainability has facilitated its growth into a diversified and vertically integrated organization. Laurus Labs caters to diverse therapeutic areas such as antiretrovirals (ARVs), oncology, hepatitis C, and other chronic diseases. Through strategic partnerships, state-of-the-art infrastructure, and a diligent team, Laurus Labs continues to deliver transformative healthcare solutions worldwide.
Laurus Labs Ltd, a leading pharmaceutical company, has achieved significant milestones over the years. One notable achievement is its successful listing on the stock exchanges in 2016, marking a significant step in its growth trajectory. The company's robust expansion plans and strategic acquisitions have further strengthened its position in the industry. Laurus Labs Ltd has also received several prestigious certifications, including the USFDA approval for its manufacturing facilities, showcasing its commitment to quality and compliance. The company's consistent revenue growth and strong financial performance have earned it recognition as one of the fastest-growing pharmaceutical companies in India.
Laurus Labs Ltd represents strong values and a robust corporate philosophy. The company focuses on delivering high-quality generic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). Laurus Labs promotes integrity, innovation, and sustainability throughout its operations. With a customer-centric approach, the company strives to provide affordable healthcare solutions globally. Laurus Labs aims to enhance access to affordable medicines while adhering to stringent quality standards. Through continuous research and development, Laurus Labs aims to develop innovative products that cater to the evolving needs of the pharmaceutical industry. The company's commitment to excellence and continuous improvement defines its corporate philosophy.
Analyytikot asettavat tällä hetkellä Laurus Labs-osakkeelle keskimääräisen tavoitehinnan 1 014,43 INR (mediaani: 1 060,80 INR), mikä merkitsee −49,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.
20 analyytikkoa arvioi tällä hetkellä Laurus Labs-osaketta: 5 suosittaa ostoa, 5 pitoa ja 10 myyntiä.
Nykyisellä valuuttakurssilla Laurus Labs-osake noteerataan hintaan 18,54 EUR (2 009,10 INR).
Laurus Labs-osake (LAURUSLABS.NS) on listattuna 2 pörssissä, muun muassa: NSE (Indien) (LAURUSLABS.NS).
Laurus Labs Ltd is a leading pharmaceutical company that delivers innovative solutions for the healthcare industry. The company has been operating in Hyderabad, India since 2005 and currently employs over 6,500 employees. The business model of Laurus Labs consists of three main divisions: generics, active pharmaceutical ingredients (API), and synthesis. The generics division focuses on manufacturing high-quality and affordable generics that are marketed worldwide. The API division produces pharmaceutical raw materials used by global pharmaceutical companies to manufacture their own products. The synthesis division produces intermediate products and specialty chemicals used in various industries such as cosmetics, agrochemicals, and polymer processing industries. Laurus Labs' products include a wide range of generics in various therapy areas such as oncology, HIV, hepatitis C, CNS, and cardiovascular. Some of the company's key medications include Abacavir, Emtricitabine, Dolutegravir, Lopinavir, Ritonavir, and Pregabalin. The company also manufactures over 50 API products including Duloxetine, Rivaroxaban, Apixaban, and Varenicline Tartrate. Laurus Labs has a strong research and development department with 400+ scientists focusing on the research of generics and innovative drugs. The company also has partnerships with several high-profile global pharmaceutical companies such as Pfizer, Aspen, Teva, and Merck. Laurus Labs has a business model focused on quality, agility, and customer orientation. The company has state-of-the-art production facilities validated according to international standards such as FDA, EU-GMP, and TGA. The company has one of the largest capacities for scaling up API products in India. The company also has a professional sales team with a strong presence in North America, Europe, and Asia. The company is also committed to achieving its sustainability goals and minimizing the environmental impact of its activities. The company has taken measures to improve energy efficiency, waste reduction, and wastewater treatment. In summary, Laurus Labs' business model is focused on a highly diversified production of generics, API, and synthesis products. The company has earned an excellent reputation for quality, agility, and customer orientation and has strong partnerships with global pharmaceutical companies. With a strong research and development department, Laurus Labs aims to continue growing in the pharmaceutical industry and delivering innovative solutions for the healthcare industry.
liikevaihto Laurus Labs on 68,13 Mrd. INR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Laurus Labs on 8,89 Mrd. INR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Laurus Labs:n hinta-voitto-suhde (P/E) on tällä hetkellä 122,20. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Laurus Labs-osakkeen arvostusta.
Laurus Labs:n hinta-myynti-suhde (P/S) on tällä hetkellä 15,94. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Laurus Labs-osakkeen arvostuskennuslukuna.
Laurus Labs:n Eulpool-laatuscore on 5/10.
Laurus Labs:n ISIN on INE947Q01028. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Laurus Labs:n ticker on LAURUSLABS.NS. Tämä pörssinoteeraus käytetään Laurus Labs-osakkeiden kauppaan pörssissä.
Laurus Labs osake
Laurus Labs vertaisryhmä
Laurus Labs Ticker
Laurus Labs FIGI
Kaikki tunnusluvut ja syvällinen analyysi Laurus Labs:sta
Meidän osakeanalyysimme Laurus Labs-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Laurus Labs:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: